Mubadala Acquires KELIX bio to further Advance UAE’s Life Sciences Ecosystem and expand its footprint in the sector

• Mubadala supporting UAE’s vision to become a global leader in the life sciences sector.
• The acquisition of KELIX bio will reinforce the UAE’s biopharma ecosystem and increase Mubadala’s presence regionally and globally.

Abu Dhabi, 25 March 2024 – Mubadala Investment Company PJSC (Mubadala), an Abu Dhabi sovereign investor, has entered into a definitive agreement to acquire KELIX bio, a specialty pharmaceutical business focused on delivering complex generics across emerging markets, to further strengthen the development of the UAE’s life sciences ecosystem, position the UAE as a global leader in the life sciences sector and to support the diversification of the economy in the UAE.

Continue reading Mubadala Acquires KELIX bio to further Advance UAE’s Life Sciences Ecosystem →